Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads In Schizophrenia & Other Psychotic Disorders
Schizophrenia & Other Psychotic Disorders for September/October 2015
First Large Trial of Aripiprazole and Risperidone, Metabolic outcomes, symptom alleviation evaluated
Cognition-Clinical Course Link in Schizophrenia, Is “pseudospecificity” an issue over time?
Schizophrenia-Dementia Link Studied in Large Cohort, Risk in those over 50 but under 65 assessed
Predicting Conversion to Psychosis , Consider using these four variables
FDA Approves Atypical Antipsychotic Aristada , Extended-release injectable for schizophrenia
Schizophrenia & Other Psychotic Disorders for July/August 2015
Clozapine’s Impact on Attention Issues , Schizophrenia patients improved in 1 of 3 areas
APA Updates Guideline for Psychiatric Evaluation, Adopts new principles; adds quality measure section
Thalamic Connectivity’s Prognostic Implications , Role in those at high risk for psychosis studied
Potential Schizophrenia Trait Marker, Study analyzes patients and unaffected siblings
Determining Paternal Age Effect, Ongoing risk factor for schizophrenia and BD
Schizophrenia & Other Psychotic Disorders for May/June 2015
Psychotic-like Symptoms in Adult Offspring, Is older parental age a risk factor?